575444-13-2

Upstream product

• 82628-68-0 3,4-dihydroxy-5-methylbenzaldehyde 
• 121-33-5 vanillin 
• 1257415-72-7 3-(benzyloxy)-4-hydroxy-5-methylbenzaldehyde 
• 488-17-5 3-methylbenzene-1,2-diol 
• 100-44-7 benzyl chloride 
• 575444-20-1 4-methoxy-3-methyl-5-triisopropylsilanyloxy-benzaldehyde 
• 209624-66-8 3-hydroxy-4-methoxy-5-methylbenzaldehyde 
• 100-39-0 benzyl bromide 
• 575444-12-1 3-(benzyloxy)-4-methoxy-5-methylbenzaldehyde 

Downstream Products

• 575444-11-0 (3S,5S,6R)-3-(3-Benzyloxy-4-methoxy-5-methyl-benzyl)-2-oxo-5,6-diphenyl-morpholine-4-carboxylic acid tert-butyl ester 
• 575444-16-5 3-[3-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-5-methyl-benzyl]-2-oxo-5,6-diphenyl-morpholine-4-carboxylic acid tert-butyl ester 
• 575444-10-9 3-[3-(tert-butyl-dimethyl-silanyloxy)-4-methoxy-5-methyl-phenyl]-2-[(9H-fluoren-9-ylmethoxycarbonyl)-methyl-amino]-propionic acid 
• 575444-17-6 (3S,5S,6R)-3-[3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-5-methyl-benzyl]-5,6-diphenyl-morpholin-2-one 
• 575444-15-4 (3S,5S,6R)-3-(3-Hydroxy-4-methoxy-5-methyl-benzyl)-2-oxo-5,6-diphenyl-morpholine-4-carboxylic acid tert-butyl ester 
• 575444-18-7 (3S,5S,6R)-3-[3-(tert-Butyl-dimethyl-silanyloxy)-4-methoxy-5-methyl-benzyl]-4-methyl-5,6-diphenyl-morpholin-2-one 
• 575444-14-3 1-Benzyloxy-5-bromomethyl-2-methoxy-3-methyl-benzene 

Relevant academic research and scientific papers

Catalytic asymmetric synthesis of the common amino acid component in the biosynthesis of tetrahydroisoquinoline alkaloids

Biosynthetic assembly lines of tetrahydroisoquinoline alkaloids employ the tyrosine derivative, (S)-2-amino-3-(3-hydroxy-4-methoxy-5-methylphenyl)propanoic acid, as a common amino acid building block. A catalytic asymmetric synthetic route to the common amino acid component has been developed by making use of Maruoka's chiral phase transfer alkylation of a glycine derivative with the requisite benzyl bromide.

Synthetic studies on ecteinascidin 743: Asymmetric synthesis of the versatile amino acid component

The asymmetric synthesis of the modified tyrosine derivative as a basic building block for the ecteinascidin and safracin family of antitumor alkaloids has been achieved in nine steps and 39% overall yield.